Recent Company News

• 10:03 AM ET Jun 11, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (204 total)

• 10:05 AM ET Jun 08, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (168 total)

• 03:49 PM ET Jun 04, 2026
  

  Transcript Intelligence: NovaBridge Biosciences at Jefferies Global Healthcare Conference ($1.80, +0.04)

• 08:21 AM ET Apr 29, 2026
  

  StreetAccount Summary - US Pre-market trading

• 06:43 AM ET Apr 29, 2026
  

  Insider transaction: NovaBridge Biosciences President and Chief Commercial Officer Mark Hagler discloses purchase of 230K shares - Form 4 (28-Apr, post-close) ($2.39, 0.00)

• 09:16 AM ET Apr 27, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 07:07 AM ET Apr 22, 2026
  

  NovaBridge appoints Mark Hagler as President and Chief Commercial Officer ($2.57, 0.00)

• 07:34 AM ET Apr 20, 2026
  

  Biogen enters into agreement to acquire TJ Biopharma's rights to felzartamab in the Greater China region ($177.35, 0.00)

• 06:55 PM ET Apr 16, 2026
  

  NovaBridge Appoints Emmett T. Cunningham, Jr., MD, PhD, MPH as Vice Chairman of the Board

• 04:53 PM ET Apr 07, 2026
  

  NovaBridge Biosciences reports FY EPADS ($0.48) vs year-ago ($0.61) ($2.48, 0.00)